XML 25 R13.htm IDEA: XBRL DOCUMENT v3.21.1
Asset Impairment, Restructuring, and Other Special Charges
 3 Months Ended
Mar. 31, 2021
Restructuring and Related Activities [Abstract]  
Asset Impairment, Restructuring, and Other Special Charges Asset Impairment, Restructuring, and Other Special Charges
The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated condensed statements of operations are described below.
Three Months Ended March 31,
20212020
Severance$11.5 $9.8 
Asset impairment and other special charges200.1 50.1 
Total asset impairment, restructuring, and other special charges$211.6 $59.9 

Asset impairment, restructuring, and other special charges recognized during the three months ended March 31, 2021 were primarily related to an intangible asset impairment of $108.1 million resulting from the decision to sell the rights to Qbrexza, as well as acquisition and integration costs associated with the acquisition of Prevail. During the three months ended March 31, 2021, we entered into an agreement to sell our rights to Qbrexza, subject to closing conditions which are expected to be completed in the second quarter of 2021. The assets associated with Qbrexza were written down to fair value less cost to sell, which were determined based upon a discounted cash flow valuation. The remaining book value of assets associated with Qbrexza subsequent to the impairment charge is not material.
Asset impairment, restructuring, and other special charges recognized during the three months ended March 31, 2020 were primarily related to acquisition and integration costs associated with the acquisition of Dermira.